SLC transporters as therapeutic targets: emerging opportunities
The DOI matches its Crossref record; 213 of the 213 references it cites were found in a registry or an index.
Abstract
Solute carrier (SLC) transporters - a family of more than 300 membrane-bound proteins that facilitate the transport of a wide array of substrates across biological membranes - have important roles in physiological processes ranging from the cellular uptake of nutrients to the absorption of drugs and other xenobiotics. Several classes of marketed drugs target well-known SLC transporters, such as neurotransmitter transporters, and human genetic studies have provided powerful insight into the roles of more-recently characterized SLC transporters in both rare and common diseases, indicating a wealth of new therapeutic opportunities. This Review summarizes knowledge on the roles of SLC transporters in human disease, describes strategies to target such transporters, and highlights current and investigational drugs that modulate SLC transporters, as well as promising drug targets.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Representative ABC transporters are multi-drug resistance protein 1 (MDR1; P-gp; ABCB1), breast cancer resistance protein (BCRP; ABCG2) and multi-drug-resistance-associated protein 1 (MRP1, ABCC1), while solute carrier (SLC) transporters include organic anion transporters, organic cation transporters and organic anion transport polypeptides [115].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [115]
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“The concentration of the substrate probe and uptake time that produce the best Z’ assay sensitivity factor is selected; a Z’ > 0.8 is ideal for HTS, although Z’ > 0.5 is also acceptable 49 .”
InfluentialHost–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722 · cited 1×
“…have been associated with human traits or disease include the following: SLC22A4 and SLC22A5, which are associated with inflammatory bowel disease 15–17 ; SLC2A9 , SLC22A11 and SLC22A12, which are associated with gout and uric acid levels 18–20 ; SLCO1B1 and SLCO1B3, which are associated with…”
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Self-citationHopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
A genome-wide association study identifies novel risk loci for type 2 diabetes
Sladek, R., Rocheleau, G., Rung, J., Dina, C., Shen, L., Serre, D., Boutin, P., Vincent, D., Belisle, A., Hadjadj, S., et al. (2007) · Nature · doi:10.1038/nature05616 · Cited by 2,993
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
Scott, L. J., Mohlke, K. L., Bonnycastle, L. L., Willer, C. J., Li, Y., Duren, W. L., Erdos, M. R., Stringham, H. M., Chines, P. S., Jackson, A. U., et al. (2007) · Science · doi:10.1126/science.1142382 · Cited by 2,753
Franke, A., McGovern, D. P. B., Barrett, J. C., Wang, K., Radford-Smith, G. L., Ahmad, T., Lees, C. W., Balschun, T., Lee, J., Roberts, R., et al. (2010) · Nature Genetics · doi:10.1038/ng.717 · Cited by 2,520
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk
The International Consortium for Blood Pressure Genome-Wide Association Studies (2011) · Nature · doi:10.1038/nature10405 · Cited by 2,033
Exome sequencing identifies the cause of a mendelian disorder
Ng, S. B., Buckingham, K. J., Lee, C., Bigham, A. W., Tabor, H. K., Dent, K. M., Huff, C. D., Shannon, P. T., Jabs, E. W., Nickerson, D. A., et al. (2010) · Nature Genetics · doi:10.1038/ng.499 · Cited by 1,957
DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1126 · Cited by 1,831
Research works printed but not linked: 1
- Feld, L. G. Renal glycosuria. Dayton Children's [online], (2003).
Cited by
A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity
Kadry, H., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00230-3 · Cited by 1,853
“This includes more than 300 transporter genes encoding membrane-bound proteins that facilitate the transport of a wide array of substrates across biological membranes [130].”
BackgroundEstablishment and Dysfunction of the Blood-Brain Barrier
Zhao, Z., Nelson, A. R., Betsholtz, C., & Zlokovic, B. V. (2015) · Cell · doi:10.1016/j.cell.2015.10.067 · Cited by 1,670
A Call for Systematic Research on Solute Carriers
César-Razquin, A., Snijder, B., Frappier-Brinton, T., Isserlin, R., Gyimesi, G., Bai, X., Reithmeier, R. A., Hepworth, D., Hediger, M. A., Edwards, A. M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.022 · Cited by 580
Understanding Cell Penetration of Cyclic Peptides
Dougherty, P. G., Sahni, A., & Pei, D. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00008 · Cited by 570
The Deubiquitylase OTUB1 Mediates Ferroptosis via Stabilization of SLC7A11
Liu, T., Jiang, L., Tavana, O., & Gu, W. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3037 · Cited by 490
Structures and General Transport Mechanisms by the Major Facilitator Superfamily (MFS)
Drew, D., North, R. A., Nagarathinam, K., & Tanabe, M. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00983 · Cited by 465
Drugging the efferocytosis process: concepts and opportunities
Mehrotra, P., & Ravichandran, K. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00470-y · Cited by 459
Emerging Diversity in Lipid–Protein Interactions
Corradi, V., Sejdiu, B. I., Mesa-Galloso, H., Abdizadeh, H., Noskov, S. Y., Marrink, S. J., & Tieleman, D. P. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00451 · Cited by 459
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
Wang, Y., Song, W., Wang, J., Wang, T., Xiong, X., Qi, Z., Fu, W., Yang, X., & Chen, Y.-G. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191130 · Cited by 399
A guide to plasma membrane solute carrier proteins
Pizzagalli, M. D., Bensimon, A., & Superti‐Furga, G. (2021) · The FEBS Journal · doi:10.1111/febs.15531 · Cited by 379
Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release
Morioka, S., Perry, J. S. A., Raymond, M. H., Medina, C. B., Zhu, Y., Zhao, L., Serbulea, V., Onengut-Gumuscu, S., Leitinger, N., Kucenas, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0735-5 · Cited by 363
Cell permeability beyond the rule of 5
Matsson, P., Doak, B. C., Over, B., & Kihlberg, J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.013 · Cited by 297
Synthetic single domain antibodies for the conformational trapping of membrane proteins
Zimmermann, I., Egloff, P., Hutter, C. A., Arnold, F. M., Stohler, P., Bocquet, N., Hug, M. N., Huber, S., Siegrist, M., Hetemann, L., et al. (2018) · eLife · doi:10.7554/elife.34317 · Cited by 280
Schneider, M., Radoux, C. J., Hercules, A., Ochoa, D., Dunham, I., Zalmas, L.-P., Hessler, G., Ruf, S., Shanmugasundaram, V., Hann, M. M., et al. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00245-x · Cited by 273
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Solute carrier transporters: the metabolic gatekeepers of immune cells
Song, W., Li, D., Tao, L., Luo, Q., & Chen, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.12.006 · Cited by 256
Mechanisms of Taxane Resistance
Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Liver Dysfunction as a Novel Player in Alzheimer’s Progression: Looking Outside the Brain
Estrada, L. D., Ahumada, P., Cabrera, D., & Arab, J. P. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00174 · Cited by 144
Direct protein-lipid interactions shape the conformational landscape of secondary transporters
Martens, C., Shekhar, M., Borysik, A. J., Lau, A. M., Reading, E., Tajkhorshid, E., Booth, P. J., & Politis, A. (2018) · Nature Communications · doi:10.1038/s41467-018-06704-1 · Cited by 134
Cross-species analysis of hepatic cytochrome P450 and transport protein expression
Hammer, H., Schmidt, F., Marx-Stoelting, P., Pötz, O., & Braeuning, A. (2021) · Archives of Toxicology · doi:10.1007/s00204-020-02939-4 · Cited by 104
Bensimon, A., Pizzagalli, M. D., Kartnig, F., Dvorak, V., Essletzbichler, P., Winter, G. E., & Superti-Furga, G. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.04.003 · Cited by 102
Ding, L., Kshirsagar, P., Agrawal, P., & Murry, D. J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060706 · Cited by 62
Chaves, J. C. S., Dando, S. J., White, A. R., & Oikari, L. E. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166967 · Cited by 62
Krchniakova, M., Skoda, J., Neradil, J., Chlapek, P., & Veselska, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093157 · Cited by 61
“While ABC transporters harness energy from ATP hydrolysis and function as efflux transporters, SLC transporters are primarily involved in the uptake of small molecules into cells, including TKIs [62] (Figure 1B).”
BackgroundRole of SLC4 and SLC26 solute carriers during oxidative stress
Remigante, A., Spinelli, S., Pusch, M., Sarikas, A., Morabito, R., Marino, A., & Dossena, S. (2022) · Acta Physiologica · doi:10.1111/apha.13796 · Cited by 44
Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response
Brackman, D. J., & Giacomini, K. M. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.903 · Cited by 31
Self-citationSNAT7 regulates mTORC1 via macropinocytosis
Meng, D., Yang, Q., Jeong, M.-H., Curukovic, A., Tiwary, S., Melick, C. H., Lama-Sherpa, T. D., Wang, H., Huerta-Rosario, M., Urquhart, G., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2123261119 · Cited by 26
Attention-based approach to predict drug–target interactions across seven target superfamilies
Schulman, A., Rousu, J., Aittokallio, T., & Tanoli, Z. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae496 · Cited by 25
Mobile barrier mechanisms for Na+-coupled symport in an MFS sugar transporter
Hariharan, P., Shi, Y., Katsube, S., Willibal, K., Burrows, N. D., Mitchell, P., Bakhtiiari, A., Stanfield, S., Pardon, E., Kaback, H. R., et al. (2024) · eLife · doi:10.7554/elife.92462.3 · Cited by 15
Mobile barrier mechanisms for Na+-coupled symport in an MFS sugar transporter
Hariharan, P., Shi, Y., Katsube, S., Willibal, K., Burrows, N. D., Mitchell, P., Bakhtiiari, A., Stanfield, S., Pardon, E., Kaback, H. R., et al. (2024) · eLife · doi:10.7554/elife.92462 · Cited by 12
Predicting substrates for orphan solute carrier proteins using multi-omics datasets
Zhang, Y., Newstead, S., & Sarkies, P. (2025) · BMC Genomics · doi:10.1186/s12864-025-11330-5 · Cited by 6
Doostparast Torshizi, A., Duan, J., & Wang, K. (2020) · Patterns · doi:10.1016/j.patter.2020.100091 · Cited by 5
Mobile barrier mechanisms for Na + -coupled symport in an MFS sugar transporter
(2023) · doi:10.1101/2023.09.18.558283 · Cited by 1
Mobile barrier mechanisms for Na+-coupled symport in an MFS sugar transporter
Hariharan, P., Shi, Y., Katsube, S., Willibal, K., Burrows, N. D., Mitchell, P., Bakhtiiari, A., Stanfield, S., Pardon, E., Kaback, H. R., et al. (2024) · doi:10.7554/elife.92462.2
Metadata
- Authors
- Lin, L., Yee, S. W., Kim, R. B., & Giacomini, K. M.
- Affiliations
- University of California, San Francisco (US)
- Western University (CA)
- Corresponding author
- Giacomini, Kathleen M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-06-26
- Volume
- 14
- Issue
- 8
- Pages
- 543-560
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2191975304
- Cited by
- 835
- References
- 213
- Citations by year
- 2026: 67 · 2025: 86 · 2024: 97 · 2023: 102 · 2022: 104 · 2021: 100 · 2020: 72 · 2019: 66 · 2018: 52 · 2017: 47 · 2016: 36 · 2015: 5
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Scholarship@Western (Western University) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (117588_1, MOP-89753)
- National Institute of General Medical Sciences (GM61390, U19GM061390, T32GM007175, U01GM061390)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK103729, DK103729, P30DK026743)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- solute carrier transporters, therapeutic target, transporter modulation, neurotransmitter transporters, monogenic disorders, rare diseases, drug absorption, xenobiotic transport, therapeutic drugs, drug repurposing
- MeSH terms
- Animals, Biological Transport, Humans, Drug Design, Xenobiotics, Drugs, Investigational, Membrane Transport Proteins, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.